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The peroxisome proliferator-activated receptor subtype γ (PPARγ) ligands, 
namely the synthetic insulin-sensitizing thiazolidinedione (TZD) compounds, 
have demonstrated great potential in the treatment of type II diabetes. However, 
their clinical applicability is limited by a common and serious side effect of 
edema. To address the mechanism of TZD-induced edema, we generated mice 
with collecting duct (CD)-specific disruption of the PPARγ gene. We found that 
mice with CD knockout of this receptor were resistant to the rosiglitazone- (RGZ) 
induced increases in body weight and plasma volume expansion found in control 
mice expressing PPARγ in the CD. RGZ reduced urinary sodium excretion in 
control and not in conditional knockout mice. Furthermore, RGZ stimulated 
sodium transport in primary cultures of CD cells expressing PPARγ and not in 
cells lacking this receptor. These findings demonstrate a PPARγ-dependent 
pathway in regulation of sodium transport in the CD that underlies TZD-induced 
fluid retention. To further study the mechanism of increased fluid reabsorption in 
the distal nephron in response to PPARγ agonist, we performed 
electrophysiological studies on primary IMCD cells to investigate the involvement 
of ENaC in mediating TZD-induced fluid reabsorption. RGZ treatment time-
dependently inhibited the activity and expression of ENaC, the major route of 
transcellular transport in the CD. However, RGZ treatment decreased the 
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transepithelial resistance. Since ENaC was suppressed, the reduction of the TER 
indicated that there is an alternative pathway in regulation of sodium transport in 
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PPARs are a group of zinc finger containing transcription factors, a 
subfamily of the nuclear hormone receptor gene family. PPARs have four major 
functional domains: an NH2-terminal ligand-independent transactivation domain 
(A/B domain), a DNA-binding domain (DBD; or C domain), a cofactor docking 
domain (D domain), and a COOH-terminal E/F domain that includes the ligand 
binding domain and the ligand-dependent transactivation domain (AF2 
domain)(1). To date, three subtypes of PPARs have been described from several 
species: PPARα, β (also called d or NUC-1), and γ (2,3,4). They share a high 
degree of similarity in their overall amino acid sequences, particularly in the DNA 
binding domain (5). The three PPARs heterodimerize with retinoid X receptor 
(RXR) and bind to the same peroxisomal proliferator-responsive element (PPRE) 
in the promoter regions of their target genes and modulate gene transcription.  
The function of PPARs is modified by the precise shape of their ligand-
binding domain induced by ligand binding and by a number of coactivator and 
corepressor proteins(4,6). These coactivators and corepressor are small 
accessory molecules that are critical determinants of the transcriptional complex. 
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The coactivators include cAMP response element-binding protein (CREB), 
PPAR-γ coactivators(PGC-1), cAMP response element-binding protein binding 
protein, and steroid receptor coactivator-1. Co-repressors such as nuclear 
receptor co-repressor (N-CoR) and silencing mediator of retinoid acid (SMRTs1) 
and thyroid hormone receptor can modulate the transcriptional activity of PPAR 
by remodeling chromatin and establishing physical contacts with transcription 
initiation machinery (7,8).  
 
PPAR ligands 
PPAR ligands include endogenous and exogenous ligands (9). 
Endogenous ligands for the PPARs include free fatty acids and eicosanoids. 
PPARα exhibiting the highest activity with unsaturated fatty acids, while saturated 
fatty acids are weak PPARα ligands in general (10). Biological modifications of 
linoleic acid, linolenic acid, eicosapentanoic acid (EPA), and arachidonic acid 
originate PPARα activators (10,11,12,13). Moreover, the oxidized form of EPA, 
eicosanoids (15-hydroxy-eicosatetranoic acid, HETE and HODEs), and 
leukotriene B4 had also been reported to be PPARα activators (1,12,13,14,15). 
PPARγ is activated by natural ligands including several prostanoids such 
as 15-deoxy-prostaglandin J2 (15d-PG J2) and 15-hydroxy-eicosatetranoic acid 
(HETE), which are metabolites of arachidonic acid (16). 15d-PG J2 (the most 
widely used natural ligand for PPARγ) is gamma-selective at low concentrations 
but also activates alpha at higher levels (17,18). Like PPARα, PPARβ/δ is 
activated by long chain fatty acids, including several polyunsaturated fatty acids 
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and eicosanoids(19). Erucic acid has been reported to be more selective for 
PPARβ/δ than other PPAR subtypes (20). 
Synthetic ligands of PPARs have been widely used to treat various 
diseases. The triglyceride-lowering/high-density lipoprotein (HDL)-raising fibrates 
(gemfibrozil, fenofibrate, clofibrate, ciprofibrate) are PPARα agonists used 
clinically to treat dyslipidemia (21,22). The insulin-sensitizing thiazolindinedione 
(TZD) class (troglitazone, pioglitazone and rosiglitazone) is PPARγ activators 
that are used to treat diabetes mellitus (23,24). Several nonsteroidal anti-
inflammatory drugs (NSAIDs), in particular indomethacin and ibuprofen, bind to 
PPARγ and are weak PPARγ agonists at high micromolar concentrations 
(25,26). The first PPARβ/δ-selective agonists (L-165041 and GW501516) were 
shown to augment HDL-C in diabetic mice as well as in obese rhesus monkeys, 
in which they results in normalization of metabolic parameters and reduction of 
fatty adiposity, which may be related to the ability of PPARβ/δ ligands to increase 
serum HDL levels (27,28). 
Distinct functions for PPAR family members are suggested from their 
tissue-specific expression patterns. PPARα mRNA is mainly expressed in liver, 
kidney, and heart, where it controls fatty acid and lipid metabolism. PPARα-null 
mice exhibit higher serum levels of cholesterol and triglycerides (29) Moreover, 
these mice display extensive hepatic lipid accumulation and increased gonadal 
adipose storage and plasma FFA levels (30). PPARß expressed widely (31,32) 
and its function remains unclear, although recent evidence suggests a key role in 
fatty acid oxidation and energy uncoupling in skeletal muscle, which leads to 
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decreased plasma triglyceride levels, increased HDL-cholesterol concentrations, 
and a lean phenotype. PPARγ modulates the expression of large gene arrays in 
adipose tissues, where it promotes adipogenesis, decreases free fatty acid (FFA) 
release, improves insulin sensitivity, and attenuates. PPARγ is highly expressed 
in fat tissues, where it controls adipocyte differentiation, lipid storage and adipose 
inflammation (33).   
 
Renal localization and function of PPARs 
Under physiological conditions, all three PPAR isoforms are expressed 
differentially in the kidney. PPARα is mainly expressed in proximal tubules and 
medullary thick ascending limbs, with lower levels in glomerular mesangial cells. 
PARβ is ubiquitously expressed at low levels in all segments of nephron, 
including in glomerular mesangial cells, medullary interstitial cells, and stromal 
cells. PPARγ is dominantly expressed in medullary collecting ducts, pelvic 
urothelium and glomerular mesangial cells. The PPARγ partner RXRα has a 
complimentary distribution the collecting ducts (34). The differences in the 
distribution PPAR isoforms may result in a different role of PPAR along urinary 
tract.  
Lots of evidence demonstrates that PPAR-alpha plays a major role in 
triggering fatty acid utilization and the adaptive response to dietary lipids in the 
kidney. One of the important pieces of evidence is found in PPAR-alpha null 
mice: fasting induced up-regulation of renal protein PDK4 expression was much 
lower than in wild type mice (35). In kidney, PPAR-beta/delta contributes to cell 
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survival of renal interstitial cell in medullary hyperosmality. Abundant and active 
PPARβ/δ was observed in cultured renal medullary interstitial cells. 
Overexpression of PPARβ/δ provides protection against hypertonicity-induced 
cell death in cultured medullary interstitial cells, which suggests that PPARβ/δ is 
an important survival factor in the kidney (35). An in vivo study by Letavernier et 
al. (36) showed that PPARβ/δ mutant mice exhibited much greater kidney 
dysfunction and injury than wild type. This protective effect was accompanied by 
a significant reduction in medullary necrosis, apoptosis, and inflammation. These 
findings point to reduced renal PPARβ/δ expression possibly representing an 
underlying mechanism involved in diabetic kidney injury. Recent studies show 
that PPAR-gamma involved in the normal kidney development, renal lipid 
metabolism, and activation of the rennin-angiotensin system. In Kidney, PPAR-
gamma is mainly expressed in the distal collecting system, as its distribution 
pattern suggests, PPAR-gamma is involved in regulating renal hemodynamic and 
water and sodium transport. Furthermore, it also participates in the pathogenesis 
of glomerulopathy, antidiabetic thiazolidinedione-related water and sodium 
retention and renal, bladder and prostate carcinomas. 
 
Distinct effects of renal PPARγ on extracellular  
volume and blood pressure 
Renal regulation of sodium and water excretion is central to the control of 
blood pressure and extracellular fluid volume. Lots of evidence suggests a 
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potential role of renal PPARγ in regulation of salt and water excretion and blood 
pressure, and this evidence can be summarized in the following categories:  
First of all is localization of PPARγ in the CD. Although sodium transport 
occurs throughout the length of the renal tubule, the fine regulation of sodium 
excretion occurs principally in the renal collecting duct (37). In the mouse kidney, 
PPARγ mRNA, determined by RT-PCR, was found to be abundant in renal inner 
medulla, localized to inner medullary collecting duct (IMCD) and renal medullary 
interstitial cells (RMIC) (38). Immunohistochemical staining of normal human 
kidney sections showed that PPARγ is highly expressed in the distal convoluted 
tubule, CCDs, and medullary CDs (39), the A6, M1, and mpkCCDc14 cells (40). 
This unique distribution pattern indicates a role of PPARγ in modulation of the 
CD function. The connective tubules and collective ducts are parts of the distal 
collecting system, where hormone-regulated ion exchange and water 
reabsorption takes place and provides the balance of interstitial fluid volume. If 
aldosterone is present, sodium is reabsorbed and potassium is secreted. Sodium 
transport is followed by passive water reabsorption, therefore, this mechanism 
regulates the total electrolytes and water volume in the body. The epithelium of 
the collecting ducts is responsive to antidiuretic hormone. If the hormone is 
present, the epithelia become permeable to water. The distal collecting system 
is, therefore, a major site of fluid volume regulation. 
Second are reduction of urinary sodium and water excretion and blood 
pressure by thiazolidinediones (TZDs). Thiazolidinediones (TZDs), synthetic 
insulin-sensitizing drugs that include troglitazone, pioglitazone, and rosiglitazone 
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(RGZ), are highly effective in the treatment of type II diabetes. TZDs are believed 
to mediate their antidiabetic effect via activation of peroxisome proliferator-
activated receptor (PPAR ) (41). In addition to lowering blood glucose, these 
drugs also benefit cardiovascular parameters, such as blood pressure and 
endothelial function (42,43). However, fluid retention, presented as rapid weight 
gain, and peripheral and pulmonary edema had emerged as the most common 
and serious side effects of TZDs (36). Song et al. reported that chronic three-day 
administration of rosiglitazone to Sprague Dawley rats significantly reduced urine 
volume (by 22%) and sodium excretion (by 44%) (44). These findings suggested 
a physiological role of PPARγ in the regulation of extracellular volume. Non-
insulin-dependent diabetes mellitus with associated insulin insensitivity and 
reactive hyperinsulinemia is often complicated by hypertension. Increased blood 
pressure could in part be due to volume expansion resulting from improper avid 
Na+ reabsorption by the kidney. Insulin increases Na+ reabsorption in the distal 
renal nephron; likely by targeting ENaC localized to the luminal membrane of 
principal cells. The highest incidence of edema has been reported when TZDs 
are utilized in combination with insulin. Global awareness of this side effect has 
increased as a result of the growing number of reported cases. In a recent issue 
of Circulation (45), the American Heart Association and American Diabetes 
Association jointly issued a Consensus Statement commenting on the safety of 
TZD as related to edema.  
Third is the stimulation of renal transporters by PPARγ activation. These 
transporters lining the renal epithelia include basolateral Na-K-ATPase, and the 
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following apical transporters that vary with individual nephron segments: the 
sodium hydrogenexchanger subtype III (NHE3) and the sodium phosphate 
cotransporter subtype II (NaPi-2) in the proximal convoluted tubule, the 
bumetanide-sensitive Na-K-2Cl cotransporter (NKCC2 or BSC1) in the thick 
ascending limb, the thiazide-sensitive Na-Cl cotransporter (NCC or TSC) in the 
distal convoluted tubule, and the amiloride-sensitive sodium channel (ENaC) in 
the collecting duct. The major water channel proteins (aquaporins, AQPs) in the 
kidney include AQP1-4, of which AQP1 and AQP2 function on the apical 
membrane, and AQP3 and AQP4 on the basolateral membrane (46). PPARγ 
activation by rosiglitazone in Sprague-Dawley rats increases protein abundance 
of various transporters, including the α-1 subunit of Na-K-ATPase, the 
bumetanide-sensitive Na-K-2Cl cotransporter (NKCC2), the aquaporins 2 (AQP2) 
and 3 (AQP3) and the sodium hydrogen exchanger (NHE3) (44). In vitro studies 
show that activation of PPARγ enhances ENaC abundance in the apical 
membrane of cultured CD cells (47).  
In contrast to the fluid retaining and prohypertensive effect of renal 
PPARγ, vascular PPARγ has been implicated to exert anti-hypertensive action. 
PPARγ is expressed in vascular system (47), such as in endothelial cells (48,49), 
vascular smooth muscle cells (VSMC) (50) and monocyte/macrophages 
(51,52,53). PPARγ activators rosiglitazone and pioglitazone prevent hypertension 
in Ang II-infused rats and abrogate the structural, functional changes induced by 
Ang II in blood vessels (54). Rosiglitazone also lowers blood pressure in 
normotensive rats and this is incompatible with enhanced fluid retention in these 
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animals (44), suggesting that the reduction of blood pressure may be attributed 
to the activation of PPARγ in vasculature but not in the kidney. 
 
Significance of the study 
 
           The mechanisms of fluid retention in patients treated with TZDs are not 
fully understood and may involve a number of factors, including reduction of 
urinary sodium excretion (2), alteration of endothelial permeability (37), increased 
sympathetic nervous system activity (40), or altered interstitial ion transport (20). 
We hypothesize that activation of PPAR  in the distal nephron may serve as the 
primary mechanism responsible for TZD-induced fluid retention. To evaluate a 
role of PPAR  in fluid retention, we built a mouse model with disrupted PPAR  
specifically in the collecting ducts (CDs) in the kidney. We found that mice with 
CD-specific knockout of PPARγ were resistant to the rosiglitazone-induced 
increase in body weight and rosiglitazone stimulated sodium transport in primary 
cultures of CDs cells expressing PPARγ but not in cells lacking this receptor (55). 
Our results were impressively complemented by the study of Guan et al. (56), 
which investigated the effects of pioglitazone and amiloride on weight gain and 
sodium retention again in knockout mice and in collecting-duct cellculture. 
Similarly, they found that deletion of CD PPARγ decreased renal Na+ avidity and 
increased plasma aldosterone. Mice treated with TZDs experience early weight 
gain from increased total body water. Moreover, weight gain was blocked by the 
diuretic amiloride. The similar effects of rosiglitazone and pioglitazone illustrate 
that stimulation of sodium transport in the collecting duct is a class effect of 
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glitazones, and proved our hypothesis that the activation of PPAR  in the distal 
nephron is the primary mechanism responsible for TZD-induced fluid retention.  
The PPARγ is reported to regulate SGK1, a protein kinase that is known 
as a key regulator of ENaC (58). PPARγ agonists have been shown to stimulate 
the transcription of the SGK1, which might enhance the surface expression of 
ENaC(39). The results suggested that PPARγ activators may increase renal Na+ 
reabsorption by stimulating ENaC and Serum- and Glucocorticoid-Regulated 
Kinase 1 (SGK1). It is believed that SGK1 expression is induced by aldosterone 
and then stimulates ENaC activity. In human CCD cells, SGK1 activity is 
stimulated by treatment with PPARγ agonists. An increase in SGK1 mRNA may 
lead to increased levels of cell surface ENaCα (39).  
However, increasing evidence has shown contradictory results indicating 
the failure of PPARγ agonists to affect ENaC activity. Nofziger et al.(2005) 
demonstrated that two PPARγ agonists, pioglitazone and GW7845, did not 
directly enhance basal or insulin-stimulated Na+ transport via ENaC in the A6, M-
1, and mpkCCDc14 cell lines. In addition, Vallon et al. recently published a study 
using mice with CD-specific conditionally inactivated αENaC (59) and patch-
clamp experiments in wild-type mice to assess the effect of PPARγ agonists on 
ENaC activity in isolated CD (60). The authors proposed that TZD-induced fluid 
retention and weight gain are mediated by nonselective cation channels in inner 
medullary CD, and ENaC-mediated Na+ reabsorption in the CD is not critical for 
this effect. To further study the exact mechanism of TZD caused excess sodium 
retention, we performed electrophysiological studies on primary cultures of inner 
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medullary collecting duct (IMCD) cells to evaluate mechanisms of rosiglitazone 
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The peroxisome proliferator-activated receptor subtype ! (PPAR!)
ligands, namely the synthetic insulin-sensitizing thiazolidinedione
(TZD) compounds, have demonstrated great potential in the treat-
ment of type II diabetes. However, their clinical applicability is
limited by a common and serious side effect of edema. To address
the mechanism of TZD-induced edema, we generated mice with
collecting duct (CD)-specific disruption of the PPAR! gene. We
found that mice with CD knockout of this receptor were resistant
to the rosiglitazone- (RGZ) induced increases in body weight and
plasma volume expansion found in control mice expressing PPAR!
in the CD. RGZ reduced urinary sodium excretion in control and not
in conditional knockoutmice. Furthermore, RGZ stimulated sodium
transport in primary cultures of CD cells expressing PPAR! and not
in cells lacking this receptor. These findings demonstrate a PPAR!-
dependent pathway in regulation of sodium transport in the CD
that underlies TZD-induced fluid retention.
roziglitazone " Cre recombinase " Evans blue technique
Thiazolidinediones (TZDs), synthetic insulin-sensitizing drugsthat include troglitazone, pioglitazone, and rosiglitazone
(RGZ), are highly effective in the treatment of type II diabetes.
TZDs are believed tomediate their antidiabetic effect via activation
of peroxisome proliferator-activated receptor ! (PPAR!) (1). In
addition to lowering blood glucose, these drugs also benefit car-
diovascular parameters, such as blood pressure and endothelial
function (2, 3). However, fluid retention, presented as rapid weight
gain, and peripheral and pulmonary edema have emerged as the
most common and serious side effects of TZDs (4–6). Global
awareness of this side effect has increased as a result of the growing
number of reported cases. In a recent issue of Circulation (7), the
American Heart Association and American Diabetes Association
jointly issued a Consensus Statement commenting on the safety of
TZD as related to edema. The mechanisms of fluid retention in
patients treated with TZDs are poorly understood and may involve
a number of factors, including reduction of urinary sodium excre-
tion (8), alteration of endothelial permeability (9), increased sym-
pathetic nervous system activity (10), or altered interstitial ion
transport (11). To evaluate the relative contributions of these
individual mechanisms, tissue- or cell-type-specific approaches are
needed in carefully designed studies.
PPARs are a group of zinc finger-containing transcription fac-
tors, representing a family of the nuclear hormone receptor gene
superfamily. To date, three subtypes of PPARs encoded by differ-
ent genes have been described from several species: PPAR", -##$,
and -! (12, 13). They share a high degree of similarity in their overall
amino acid sequences, particularly in the DNA-binding domain
(14). The three isoforms of the PPARs heterodimerize with reti-
noid X receptor, bind to the same peroxisome proliferator-
responsive element in the promoter regions of their target genes,
and modulate gene transcription (13). Distinct functions for PPAR
family members are suggested from their tissue-specific expression
patterns: PPAR" is mainly expressed in liver, kidney, and heart,
where it controls fatty acid and lipid metabolism; PPAR! is highly
expressed in fat tissues, where it controls adipocyte differentiation
and lipid storage; and PPAR$ is widely (15) expressed and its
function largely remains unclear, although recent evidence suggests
a role in fatty acid and lipid metabolism (16).
Within the kidney, PPAR! is predominantly expressed in the
inner medulla and in the inner medullary collecting duct (CD) (17,
18), a critical site for the control of fluidmetabolism. Therefore, we
hypothesize that activation of PPAR! in the distal nephron may
serve as the primarymechanism responsible for TZD-induced fluid
retention. To examine this hypothesis, the present study uses the
Cre-loxP system to generate mice with CD-specific deletion of
PPAR!. The CD PPAR! knockout (KO) mice were generated by
genetic cross between PPAR! floxed mice and transgenic mice
expressing Cre recombinase under the control of the mouse AQP2
promoter. We report that TZD-induced fluid retention is remark-
ably blocked in CD PPAR! KO mice as compared with controls.
Methods
Transgenic Mice. We generated mice with CD-specific KO of the
PPAR! gene by genetic cross between PPAR! floxed mice and
AQP2-Cre mice. The PPAR! floxed mice contain two loxP sites
inserted into introns 1 and 2 of the PPAR! gene flanking the critical
exon 2 by homologous recombination in ES cells (19). AQP2-Cre
mice contain a transgene, with 11 kb of the mouse AQP2 gene 5!
flanking region driving expression of the Cre recombinase (20).
Both PPAR! floxed and AQP2-Cre mice were phenotypically
normal. Homozygous PPAR! floxed (PPAR!f/f) mice were mated
with female AQP2-Cre mice to yield mice heterozygous for floxed
PPAR! and heterozygous for AQP2-Cre. These mice were bred
with mice homozygous for floxed PPAR! to obtain mice homozy-
gous for floxed PPAR! (termed CD PPAR! KO).
All animal procedures were approved by the University of Utah
Institutional Animal Care and Use Committee.
Genotyping.The genotype of theAQP2-Cremice was performed as
described (20). Genotyping the PPAR! gene involved the use of
primers PPAR! F1 (5!-CTCCAATGTTCTCAAACTTAC-3!)
and PPAR! R1 (5!-GAT GAGTCATGTAAGTTGACC-3!),
which yielded a 225-bp band from the wild-type allele and a 275-bp
band from the floxed allele. The DNA recombination was assessed
in both kidney regions and microdissected nephron segments.
Renal cortex and inner medulla from CD PPAR! KO and
PPAR!f/f mice were dissected and subjected to DNA extraction by
using TRIzol reagent. The DNA was amplified by using primers
PPAR! F2 (5!-GACAGCACAACA ATGTTCCCA-3!) and
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PPAR! R2 (5!-GTATTCTATGGCTTCCAGTGC-3!), which
flanked the loxP sites and yielded a 2,423-bp band from the floxed
allele and a 438-bp band from the recombined allele. To evaluate
the CD-specific recombination event, CD PPAR! KO mice were
anesthetized by isoflurance, and the left kidney was perfused with
DMEM containing 2 mg#ml each collagenase Type 1 (Worthing-
ton) andhyaluronidase (Sigma).Kidney sliceswere incubated in the
same solution for 45min at 37°C. Under a stereomicroscope, 20–30
of each of the following nephron segments, including glomerulus,
proximal convoluted tubule, cortical andmedullary thick ascending
limb, cortical and inner medullary CD, were dissected. The recom-
bined allele from the microdissected nephron segments was de-
tected as a 438-bp band by using primers PPAR! F2 and PPAR!
R2and the floxed allele as a 1,419-bp bandby using primers PPAR!
F3 (5!-CTCCAATGT TCTCAA ACTTAC-3!) and PPAR! R3
(5!-CATGAACTCCATAGTGGA AGCC-3!). Because PPAR!
R3 was positioned within the loxP sites, no band was detected from
recombined allele by using PPAR! F3 and PPAR! R3.
RGZ Treatment and Metabolic Studies. RGZ was incorporated into
a chow-based diet (LabDiet Rodent Chow 5001; Purina) at a level
of 320 mg#kg diet. RGZ was made by GlaxoSmithKline and
purchased from the University of Utah Hospital. The gelled diets
were made bymelting agar (1% by weight) in water (65%), cooling,
and adding the drug (0.1%), ground chow (33.9%), and NaCl
(0.5%). The final content of NaCl became 0.8%. The same gelled
diets without the drug served as controls. Adult PPAR!f/f and CD
PPAR!KOmice (3"4-month-old) were acclimatized to metabolic
cages (Hatteras Instruments, Cary, NC) and the control diet for 7
days. The numbers of males and females were roughly even in each
group. After the 7-day acclimation period, PPAR!f/f and CD
PPAR! KO mice were placed on the gelled diet with or without
RGZ for 9 days. Measurements of body weight and collection of
24-hour urine were performed. Hematocrit (Hct) was measured
before and after RGZ treatment; at the end of experiments, plasma
volume and blood pressure were determined as described in the
following.
Measurement of Hct. The sphenous vein was punctured by using a
#23-gauge needle, and one drop of blood (#5–10%l) was collected
by using a 10-%l capillary glass (Idaho Technology, Salt Lake City).
One side of the tube was sealed with Hemato-Seal and then
centrifuged for 4 min in a Thermo IEC (Boston) microcentrifuge
machine.
Measurements of Plasma Volume and Blood Pressure.Under general
anesthetization with isoflurane (2 ml#min), catheters were placed
in the carotid artery for direct measurement of systolic blood
pressure and in the jugular vein for infusion of Evans blue. Blood
pressure was recorded by using a pressure transducer (Abbott
Critical Care System) and a data acquisition system (Dataq Instru-
ments, Akron, OH). After recording of blood pressure for 5 min,
25 %l of 2 mg#ml Evans blue was injected via jugular vein cathe-
terization. Seven minutes later, #700–800 %l of blood was with-
Fig. 1. Validation of CD-specific KO of PPAR!. (a) Colocalization of YFP
expression and AQP2 immunofluorescence in mice doubly heterozygous for
ROSA26-YFP andAQP2-Cre. A representative photomicrograph is shown from
three separate animals ($600). (b) PCR analysis of AQP2-Cremediated recom-
bination of the PPAR! gene in the inner medulla and cortex. Null band (438
bp) is the recombination product after deletion of exon 2 of the PPAR!. Exon
2 was nearly completely deleted in the inner medulla and partially deleted in
the cortex of CD PPAR! KOmice (n% 3) as compared with the floxed controls
(n % 2). (c) PCR analysis of AQP2-Cre-mediated recombination of the PPAR!
gene in microdissected nephron segments from PPAR! KOmice. (d) Immuno-
cytochemistry analysis of PPAR! protein expression in CD cells derived from
PPAR! KO mice. CD cells were isolated by using lectin-coated dynabeads and
grown in a chamber slide. Immunocytochemistry was performed by using a
polyclonal antibody against PPAR!. Shown is a representative from three
separate experiments.
Table 1. Routine physiological data
PPAR!f#f CD PPAR! KO
Vehicle (n % 4) RGZ (n % 5) Vehicle (n % 4) RGZ (n % 4)
Plasma Na, mmol#l 157 & 0.95 162 & 3.15 158 & 1.65 162 & 1.33
Plasma K, mmol#l 4.08 & 0.1 4.55 & 0.36 3.9 & 0.17 4.2 & 0.03
Plasma Cl, mmol#l 109 & 0.91 112 & 2.84 109 & 2.40 113 & 0.67
Plasma creatinine, mg#dl 1.02 & 0.06 0.9 & 0.04 0.95 & 0.028 1 & 0.00
Plasma BUN, mg#dl 27 & 3.24 29 & 2.86 26 & 1.87 26 & 3.21
Urine volume, %l#24 hr 1625 & 188.68 1,749 & 257.11 1,904 & 199.27 1,762 & 152.46
Urine creatinine, mg#dl 20.33 & 3.60 25.5 & 4.69 21.75 & 1.15 19.6 & 1.63
ClCr, ml#min 0.22 & 0.02 0.30 & 0.02 0.30 & 0.05 0.25 & 0.05
SBP, mmHg 112.67 & 4.67 107.50 & 2.75 123.50 & 7.77 117.25 & 6.85
ClCr, creatinine clearance; SBP, systolic blood pressure. No statistical significance was found between any
groups.








drawn from the vena cava by using a heparin-coated 1-cc syringe
with bent #23-gauge needle. Plasma was separated by centrifuga-
tion of the blood at 5,000$ g for 4min. Absorbance was read at 620
nm, and plasma Evans blue concentrations were calculated accord-
ing to a standard curve generated by a serial dilution of the 2mg#ml
Evans blue-saline solution. Plasma volume was calculated by using
the dilution factors of Evans blue.
Aldosterone RIA. Plasma aldosterone concentrations were deter-
mined by using Coat-A-Count RIA kit (Diagnostic Products, Los
Angeles). Twenty microliters of plasma was diluted with 100 %l of
diluent before the assay.
Primary Cultures of CD Cells and Measurements of Sodium Transport.
The primary cultures of CD cells derived from the whole kidneys
of PPAR!f/f and CD PPAR! KO mice were performed by using
lectin-coated Dynabeads, as described (21).
For measurements of sodium transport, the CD cells were
subcultured onto permeable filter supports (0.4-%m pore size,
1.13-cm2 surface area; Transwell, Corning Costar). Cells were kept
on filters for at least 10 days until a confluent transporting cell
monolayer had developed. This was evaluated by measurement of
the [14C]-inulin leak, as described (22). Transepithelial resistance
was determined by using ‘‘chopstick’’ electrodes (EVOM, World
Precision Instruments, Sarasota, FL). Transepithelial transport of
22Na was determined by adding 10 %Ci (1 Ci% 37 GBq) of 22Na to
the apical compartment followed by measurement of the radioac-
tivity in the basal compartment. All studies described in this report
were performed on cells between the third and fifth passages.
Statistical Analysis. Values shown represent means&SE. Statistical
analysis was performed by unpaired t tests or ANOVA and Bon-
ferroni tests, with a P value of '0.05 being considered statistically
significant.
Results
Generation ofMicewith CD-Specific KO of PPAR!.ThePPAR! floxed
mice, containing two loxP sites inserted into introns 1 and 2 of the
PPAR! gene flanking the critical exon 2, were generated by
homologous recombination in ES cells (19). AQP2-Cre transgenic
mice expressing Cre under the control of mouse AQP2 promoter
(20) were used to produce a CD-specific disruption of the PPAR!
gene. To assess CreTag activity in vivo, AQP2-Cre mice were bred
with reporter mice (ROSA26-YFP). YFP expression was restricted
to kidney and testes but not other tissues examined, including lung,
brain, heart, muscle, intestine, stomach, spleen, and liver (data not
shown). In the kidney, YFP expression was found in AQP2-
expressing CD cells (Fig. 1a). Homozygous PPAR! f loxed
(PPAR!f/f) mice were mated with female AQP2-Cre mice to yield
mice heterozygous for the floxed PPAR! allele and heterozygous
for the AQP2-Cre transgene. These mice were bred with mice
homozygous for the floxed PPAR! to obtain mice homozygous for
the floxedPPAR! (termedCDPPAR!KO).CDPPAR!KOmice
had no gross morphological abnormalities until at least 6 months
of age.
The 438-bp products derived from the recombined allele were
detected in both the inner medulla and cortex of CD PPAR! KO
mice but not in those of PPARf/f mice (Fig. 1b). The 2,423-bp
products derived from the floxed allele were almost undetectable
in the inner medulla and were substantially reduced in the renal
cortex of CD PPAR!KOmice, compared with the floxed controls.
To confirm the CD-specific recombination, microdissected
nephron segments from CD PPAR! KO mice were examined for
the existence of the floxed and recombined alleles. The recombined
allele, detected as a 438-bp band, was found only in theCD (cortical
and inner medullary CDs) but not in other segments; the floxed
Fig. 2. Body-weight gains in un-
treated and RGZ-treated PPAR!f/f
mice (a) and CD PPAR! KOmice (b).
PPAR!f/f per vehicle, n % 11;
PPAR!f/f per RGZ, n % 9; CD PPAR!
KO per vehicle, n% 8; CD PPAR! KO
group, n % 9. *, P ' 0.05 vs. vehicle
at the corresponding time point.
Fig. 3. Changes in plasma volume in PPAR!f/f and CD PPAR! KO mice after
RGZ treatment. (a) Hct in PPAR!f/f andCDPPAR!KOmicebefore andafter RGZ
treatment. PPAR!f/f per vehicle, n % 4; PPAR!f/f per RGZ, n % 5; CD PPAR! KO
per vehicle, n% 4; CD PPAR! KO group, n% 4. (b) Plasma aldosterone levels in
PPAR!f/f and CD PPAR! KOmice after RGZ treatment. n% 4 in each group. (c)
Determinationof plasma volumePPAR!f/f andCDPPAR!KOmice by the Evans
blue technique. PPAR!f/f per vehicle, n% 5; PPAR!f/f per RGZ, n% 6; CD PPAR!
KO per vehicle, n % 4; CD PPAR! KO group, n % 4.
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allele, detected as 1,419-bp band, was present inGlom, PCT, cTAL,
andmTAL, but was almost undetectable in the CD (Fig. 1c). Using
lectin-coated Dynabeads, we isolated CD cells from PPAR!f/f and
CD PPAR! KO mice. The PPAR!f/f cells expressed abundant
PPAR! protein mostly in the nucleus, as assessed by immunocy-
tochemistry. In contrast, PPAR! protein expression in the PPAR!
KO cells was markedly reduced (Fig. 1d).
Comparison of Body Weights. TZDs induce body weight gain in both
humans and rats as a result of fluid retention. Therefore, we
monitored changes in body weights in PPAR!f/f and CD PPAR!
KO mice after a 9-day RGZ treatment. We found that RGZ
induced a gradual and significant increase in body weights in the
floxedmice as compared with the untreated floxed animals (2.74&
0.25 vs. 1.05( 0.16 g on day 9, P' 0.05). In contrast, body weight
gains between RGZ-treated and untreated CD PPAR! KO mice
were not significantly different (0.90 & 0.25 vs. 0.81 & 0.19 g on
day 9, P ) 0.05) (Fig. 2).
Comparison of Plasma Volumes. We monitored Hct changes in
PPAR!f/f and CD PPAR! KO mice before and after RGZ
treatment. Blood samples were collected from the sphenous vein
in awake animals for determination of Hct. RGZ treatment
consistently induced a fall of Hct from 51.0 & 2.3% to 45.0 &
1.2% (P ' 0.01) in PPAR!f/f mice (Fig. 3a). A trend for a
reduction of Hct was seen in CD PPAR! KO mice but did not
reach statistical significance.
Plasma aldosterone levels are widely used as a reliable index of
plasma volume. Thus we compared RGZ-induced changes in
plasma aldosterone levels between the two strains of mice. We
observed a significant fall of plasma aldosterone levels in PPARf/f
mice after RGZ treatment, in contrast to the insignificant changes
in CDPPAR!KOmice (Fig. 3b). The pattern of changes in plasma
aldosterone levels was similar to those in Hct levels.
To confirm the results obtained with indirect measurements, we
used the Evans blue technique to accurately measure plasma
volume. The Evans blue technique is widely used to determine
plasma volume in humans (23, 24), dog (25), and rat (26). Plasma
volume in untreated PPARf/f mice was 62.5 & 1.6 %l per gram,
which approximates the value of 54& 7 ml#kg in dog (25). A 9-day
RGZ treatment induced a 32.2% increase in plasma volume in
PPAR!f/f mice. In the basal state, CD PPAR! KO mice had a
normal plasma volume that was not significantly different from the
floxed controls. However, the KOmice had a significantly reduced
plasma volume expansion induced by RGZ (Fig. 3c).
Comparison of Sodium Balance.We performed metabolic studies to
determine sodium intake and excretion in PPAR!f/f and CD
PPAR! KO mice before and after RGZ treatment. After RGZ
treatment, PPARf/f mice had unchanged sodium intake but a
significant reduction of urinary sodium excretion that peaked at day
6 and returned to normal at day 8; CD PPAR! KO mice did not
exhibit significant changes in either sodium intake or urinary
sodium excretion (Fig. 4 a–d). Sodium balance was further deter-
mined by subtracting output from intake. RGZ treatment induced
a positive sodium balance in the controlmice but not in CDPPAR!
KO mice (Fig. 4 e and f).
Comparison of Sodium Transport in the Primary Culture of CD Cells.
We attempted to address the cellular mechanism of differences in
the RGZ-induced plasma volume expansion between PPARf/f and
CD PPAR! KO mice. Therefore, we established primary cultures
Fig. 4. Comparison of urinary so-
dium excretion and sodium intake
between PPRA!f/f and CD PPAR! KO
mice. After a 7-day acclimation pe-
riod, PPRA!f/f and CD PPAR! KO
mice were treated for 9 days with
the gelled diet incorporated with
or without RGZ. Shown are daily
sodium intake (a and b), urinary so-
dium excretion (c and d), and so-
dium balance (intake–output) (e
and f ). n % 9 in each group. *, P '
0.05 vs. vehicle; #, P ' 0.001 vs. ve-
hicle at the corresponding time
point.








of CD cells derived from the two strains of mice for a parallel
examination of sodium transport in response to RGZ treatment.
We used biotinylated Dolichos biflorus agglutinin-coated Dyna-
beads to isolated CD cells. These cells exhibited epithelial cell like
morphology (Fig. 5a). In the basal state, they expressed abundant
AQP2 mostly in cytoplasm as assessed by immunocytochemistry
(Fig. 5b). Cell morphology between the control and CD PPAR!
KO cells was not obviously different nor was the expression of
AQP2. For measurements of sodium transport, the CD cells were
subcultured onto permeable filter supports. Measurement of 14C-
inulin leak across the monolayers was performed to determine
whether confluent cells were a tight monolayer. The leak of
14C-inulin from the apical to basal was 0.46 & 0.12% and 0.87 &
0.24% in the period of 10 min and 1 h, respectively. There were no
differences detected between the control and PPAR KO cells
(0.58 & 0.21% vs. 0.35 & 0.01% at 10 min, and 0.90 & 0.35% vs.
0.83& 0.37%at 1 h, respectively,P) 0.05). Exposure of the control
cells to 1 %M RGZ for 24 h significantly reduced transepithelial
resistance in an amiloride-sensitivemanner, suggesting activation of
epithelial sodium channel (ENaC)-mediated sodium transport (Fig.
5c). In contrast, the same RGZ treatment had no obvious effect on
transepithelial resistance in the CD PPAR!KO cells. Similarly, the
RGZ treatment induced a significant increase in transepithelial
22Na flux in the control cells in an amiloride-sensitive manner. The
RGZ-induced changes in 22Na flux were significantly blocked in the
PPAR! KO cells.
Discussion
The PPAR! activators, TZDs, are insulin-sensitizing agents that
improve insulin sensitivity as well as parameters of blood pressure
and endothelial function. Currently, two TZDs, RGZ and piogli-
tazone, are being widely used for the treatment of type II diabetes
as efficient insulin sensitizers alone or in combination with other
antidiabetic agents such as metformin, sulfonylureas, or insulin.
However, these drugs are associated with significant fluid retention
as the most common and serious side effect. The current study
describes a Cre-Loxp approach to testing the role of CD PPAR! in
TZD-induced fluid retention. To achieve CD-specific deletion of
PPAR!, we used the mouse AQP2 promoter to drive Cre expres-
sion specifically in the CD. Specific recombination in the CD was
validated by PCR on microdissected nephron segments. A 9-day
RGZ treatment consistently increased body weight in PPAR!f/f but
not in CD PPAR!KOmice. After RGZ treatment, PPAR!f/f mice
exhibited severe plasma volume expansion, as reflected by signif-
icant decreases in Hct and plasma aldosterone levels, and increases
in plasma volume, as measured by the Evans blue technique. In
contrast, the RGZ-induced plasma volume expansion was remark-
ably blunted in CD PPAR! KO mice.
It is well documented that TZD-induced edema is caused by
a positive sodium balance (intake ) excretion). In this regard,
Song et al. (27) reported that chronic 3-day administration of
RGZ to Sprague–Dawley rats significantly reduced urine volume
(by 22%) and sodium excretion (by 44%). Because electrolyte
and water metabolism are largely maintained at the renal level,
it is reasonable to speculate that renal mechanisms will play a
major role in TZD-induced fluid retention. Within the kidney,
PPAR! is highly expressed in the renal medullary CD, with
lower expression levels in glomeruli, proximal tubules, and
microvasculature, as demonstrated by both RT-PCR and micro-
dissection and by in situ hybridization techniques (17, 18, 28).
This distribution pattern suggests the possibility that local acti-
vation of PPAR! in the CD may stimulate sodium reabsorption
and account for the fluid retention. This notion is supported by
several lines of direct and indirect evidence from previous
studies. First, in a cultured human cortical CD cell line, PPAR!
agonists increase levels of cell surface ENaC", paralleled by
stimulation of gene expression of serum and glucocorticoid
regulated kinase 1 (SGK1), a key mediator of aldosterone
activation of ENaC (29). Second, a PPAR! ligand, GI262570,
increased expressions of ENaC", SGK1, and Na-K-ATPase" in
the renal medulla (26). Finally, GI262570 caused sodium reten-
tion but did not affect glomerular filtration rate, renal plasma
flow, and renal filtration fraction (30, 31), indirectly supporting
the local action of TZDs. In line with these observations, we
report that RGZ-induced plasma volume expansion was signif-
icantly blunted in PPAR! KO mice. Taken together, the obser-
vations from these previous along with our current studies
provide solid evidence supporting a role for the distal nephon in
fluid retention associated with TZDs.
Compared with control (PPAR!f/f) mice, CD PPAR! KO mice
exhibited a significantly blunted response to RGZ, as revealed by
the extent of fluid retention; however, they still showed trends in
changes inHct, aldosterone, and plasma volume. The reason for the
residual responses remaining in PPAR KO mice is unclear. One
possibility is that this residual response may be due to incomplete
PPAR! deletion in the CD. However, the nearly complete absence
of PCR products derived from the unrecombinant allele from the
innermedulla and theCDofCDPPAR!KOmice does not support
this possibility. Apart from the distal nephron, other sites of action
of TZDs may also contribute to fluid retention. PPAR! agonists
decrease lithium clearance in humans, suggesting some stimulation
Fig. 5. Comparison of sodium transport between the cultured CD cells
derived from PPAR!f/f and CD PPAR! KO mice. (a) Phase-contrast micrograph
of confluent CD cells derived from PPAR!f/f and CD PPAR! KO mice. (b) AQP2
immunocytochemistry showing AQP2 expression in the unstimulated control
and CD PPAR! KO cells. (c) Changes of transepithelial resistance (RTE) in the
control and CD PPAR! KO cells after RGZ treatment. (d) Changes in 22Na flux
in the control and PPAR! KO cells after RGZ treatment.
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of reabsorption in the proximal tubules (32). Several proximal
tubule transporters including sodium hydrogen exchanger-3 un-
dergo changes in gene expression in response to RGZ treatment
(27). However, these observations are not supported by the finding
that PPAR! mRNA is not detected in proximal tubules (18).
PPAR! is expressed in the vascular system (33), such as in
endothelial cells (34, 35), vascular smooth muscle cells (36), and
monocyte#macrophages (37, 38), where TZDs may affect vascular
function, leading to edema. In line with this notion, PPAR!
activators RGZ and pioglitazone prevent hypertension as well as
the vascular changes induced by angiotensin II infusion (39). RGZ
also lowers blood pressure in normotensive rats (27). A recent study
by Ryan et al. (40) showed that TZDs exerted a direct vasodilatory
effect in isolated carotid artery but through PPAR!-independent
mechanisms. Overall, other sites than the distal nephron, such as
the vasculature, may still contribute to the TZD-induced fluid
retention; however, any contribution from these sites is unlikely to
be significant.
It is conceivable that the TZD-induced fluid retention is medi-
ated by a PPAR!-dependent activation of sodium transport in the
distal nephron. Therefore, primary cultures of CD cells derived
from PPAR!f/f and CD PPAR! KO mice were established for
parallel examination of sodium transport in response to RGZ
treatment. In control cells, RGZ treatment had a direct stimulatory
effect on sodium transport, as assessed by both transepithelial
resistance and transepithelial 22Na flux. In sharp contrast, the RGZ
effect was almost completely blocked in the CD PPAR! KO cells.
These observations strongly suggest that the stimulatory effect of
RGZ on sodium transport is mediated by PPAR!, ruling out
nonspecific mechanisms. It is evident that PPAR! functions as a
positive regulator of sodium transport process in the distal nephron,
which likely underlies TZD-induced fluid retention.
Besides addressing the mechanism of TZD-induced fluid reten-
tion, the data presented in the present study strongly support the
notion that PPAR! may function as a physiological regulator of
sodium transport process in the distal nephron. In cases of modest
changes in sodium intake, CDPPAR!KOmice do not exhibit signs
of altered balance of electrolytes and water. These findings suggest
that PPAR! in the distal nephron is not required for the mainte-
nance of fluid homeostasis in the normal physiological state.
However, this does not rule out the possibility that PPAR!mayplay
a role under more stressful conditions with significant changes in
salt or water intake. If PPAR! serves as a physiological regulator
of the CD function, a question arises as to what is the endogenous
ligand for the nuclear receptor. 15-deoxy-Delta(12,14)-prostaglan-
din J2 (15d-PGJ2), a product of prostaglandin D2, is an effective
activator of PPAR! in several in vitro systems (41, 42).Despite some
evidence for endogenous biosynthesis of 15d-PGJ2 in a number of
cell types (43, 44), it remains uncertain whether 15d-PGJ2 is
produced in the kidney in a sufficient amount to act as an effective
endogenous ligand for PPAR! in vivo.
Conclusion
The present study generated mice with CD-specific deletion of
PPAR! by genetic cross between PPAR! floxed mice with trans-
genic mice expressing Cre under the control of the mouse AQP2
promoter. After chronic treatment with the PPAR! ligand, control
mice developed severe volume expansion in sharp contrast to the
significantly blunted response in CDPPAR!KOmice. Overall, our
study provides insight into TZD-induced edema and also suggests
an area of research concerning PPAR!-dependent mechanisms for
the control of fluid homeostasis.
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THE MECHANISM BY WHICH PPARγ AGONISTS 
 INDUCED FLUID RETENTION 
 
Introduction  
Peroxisome proliferator-activated receptor gamma  (PPARγ) is a nuclear 
receptor and a member of the NR1C subgroup that includes PPARα and PPARδ.  
These receptors heterodimerize with the retinoid X receptor (RXR) and bind to 
PPAR responsive elements in the regulatory region of target genes. PPARγ is 
most abundantly expressed in the adipose tissue where it plays a pivotal role in 
driving adipocyte differentiation and maintaining adipocyte specific functions, 
such as lipid storage in the white adipose tissue and energy dissipation in the 
brown adipose tissue (1-6).  In addition, PPARγ is a key regulator of glucose 
metabolism through improvement of insulin sensitivity. This insulin sensitizing 
activity affords the therapeutic potential of PPARγ activation in management of 
hyperglycemia and insulin resistance in type 2 diabetes.  Recently, growing 
evidence suggests that PPARγ possesses anti-inflammatory property, 
representing additional benefits in limiting atherosclerosis or other inflammatory 
processes directly or indirectly related to diabetes (7). Among synthetic 
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compounds that activate PPARγ, thiazolidinediones (TZDs), including Actos 
(pioglitazone) and Avandia (RGZ), display remarkable enhancement of insulin 
action and improvement of glycemic control in patients with type 2 diabetes (8,9).   
Despite their proven efficacy, TZDs possess a number of deleterious side 
effects.  Fluid retention has emerged as the most common and serious side 
effect of TZDs(10-12). The incidence of TZD-induced fluid retention ranges from 
7% in monotherapy and to as high as 15% when combined with insulin (10-12).  
The fluid retention is often presented as peripheral edema, which can progress 
into pulmonary edema and congestive heart failure. TZD use leads to a 6-7% 
increase in blood volume in healthy volunteers (13,14).  Global awareness of this 
side effect has increased as a result of the growing number of reported cases.  
American Heart Association and American Diabetes Association jointly issued a 
Consensus Statement commenting on the safety of TZD as related to edema 
(15). Although multiple factors may be involved, increased fluid reabsorption in 
the distal nephron appears to be a major determinant of TZD-induced fluid 
retention. In this regard, PPARγ expression is predominatly expressed in the 
collecting duct (16,17). More importantly, conditional deletion of PPARγ in the 
collecting duct remarkably attenuated RGZ- or pioglitazone-induced body weight 
gain and plasma volume expansion found in wild type mice (18,19).   
Transcellular transport of Na+ in the CD is mainly mediated by ENaC, 
which is comprised of three subunits, α, β, and γ. These proteins are vital to day-
to-day adjustment of urinary Na+ excretion and are subjected to hormonal 
regulation by aldosterone, insulin, and vasopressin (20-22). A number of studies 
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examined the possibility of PPARγ regulation of ENaC and yielded conflicting 
results (19,23,24). The goal of the present study is to examine involvement of 
ENaC in PPARγ-dependent stimulation of ion transport.  
 
Materials and methods 
Materials  
 Amiloride and epidermal growth factor (EGF) were purchased from 
Sigma. DMEM medium was from American Type Culture Collection (ATCC) 
(Manassas, VA). Snapwell permeable supports were from Corning Incorporated 
(Corning, NY). Collagen type I was from Worthington Biochemical Corp. 
(Lakewood, NJ).  
 
Animals   
C57/BL6 mice were purchased from Jackson Laboratory and were used 
as wild type mice. Collecting duct-specific PPARγ knockout (CD PPARγ KO) 
mice were generated by crossing PPARγ floxed mice with mAQP2-Cre mice and 
were used only in the ion substitution experiments. All mice were maintained in a 
temperature-controlled barrier facility with a 12 h/12 h light/dark cycle and were 
given free access to standard laboratory chow and tap water. All protocols 
employing mice were conducted in accordance the principles and guidance of 
Institutional Animal Care and Committee at the University of Utah.  
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RGZ treatment  
RGZ was incorporated into a chow-based diet (LabDiet Rodent Chow 
5001; Purina Mills, St. Louis, MO) at a level of 320 mg/kg diet. The gelled diets 
were made by melting agar (1% by weight) in water (65%), cooling and adding 
the drug (0.1%), and ground chow (33.9%), and NaCl (0.5%). The final content of 
NaCl became 0.8%. The same gelled diets without the drug served as controls. 
Adult PPARγf/f and CD PPARγ KO mice (3~4-month-old) were acclimatized to 
metabolic cages (Hatteras Instruments) and the control diet for 7 days.  The 
numbers of males and females were roughly even in each group.   After the 7-
day acclimation period, PPARγf/f and CD PPARγ KO mice were placed on the 
gelled diet with or without RGZ, for 9 days.  At the end of experiments, under 
anesthesia, kidneys are harvested and processed for evaluation of the states of 
sodium transporters including various isoforms of ENaC and Na-K-ATPase. 
Gene expression levels of the transporters will be determined by qRT-PCR.  
 
Cell culture  
Mice were killed by cervical dislocation and kidneys were quickly removed 
under sterile conditions. The renal inner medulla was dissected, minced, and 
digested for 60 min in 10 ml of DMEM medium containing 0.2% collagenase type 
I, 0.2% hyaluronidase, and 0.025% trypsin-EDTA at 37 ºC with shaking. After 
incubation, 20 ml of sterile distilled water was added for 20 min to lyse cells other 
than collecting duct cells by osmotic shock (100 mOsm/kg·H20). Cells were then 
centrifuged at 1,000 rpm for 5 min, the supernatant was discarded, and the pellet 
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resuspended in the modified medium (DMEM, 10% fetal bovine serum, 20 ng/ml, 
and 100 units/ml penicillin G-streptomycin sulfate). Cells were seeded onto 
semipermeable 12-mm-diameter Snapwell membranes for electrophysiological 
studies. After the cells reached confluence, usually in 10 days, the cells were 
incubated in serum-free media for at least 4 h before experiments. The cell 
monolayers were confirmed to be confluent by development of high resistance. 
The short-circuit current (Isc) and the transepithelial voltage (Vte) were 
determined by using VCC600 voltage clamp apparatus (Physiologic instruments, 
San Diego, CA, USA).  The transepithelial resistance (TER) was measured by 
using EVOM epithelial volt-ohm-meter and a set of two stick STX electrodes 
(World Precision Instruments, Sarasota, Fl, USA). Only the cell monolayers 
reaching the resistance >1000 Ω.cm2 were used for electrophysiological studies.  
 
Electrophysiological transepithelial measurements 
 Snapwell semipermeable membranes containing confluent cell 
monolayers were mounted in an Ussing chamber (Physiologic instruments, San 
Diego, CA, USA) and both surfaces of the cell monolayer were bathed in 
completed media (NaCl, 120 mM; KCl, 4.2 mM; NaHCO3, 34 mM; MgCl2, 0.3 
mM; Na2HPO4, 1mM; MgSO4, 0.4 mM; CaCl2, 1.05 mM; glucose, 20 mM) 
maintained at 37 ºC and equilibrated in 5% CO2-95% O2 to keep pH at 7.4. The 
transepithelial voltage was clamped at zero using VCC600 voltage clamp 
apparatus, and then the short-circuit current (Isc) was recorded using Ag-AgCl 
electrode in agar brides after 60 min equilibration period. Positive Isc reflects the 
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active transport of cation (Na+) from apical side to basolateral side media or 
transport of anion (Cl-) from apical to basolateral side of media. 
 
qRT-PCR  
Total RNA was isolated from primary IMCD cells using TRIzol. One 
microgram of total RNA was denatured at 65°C for 5 min, and cDNA synthesis 
was then performed at 42°C for 1 h using Superscript reverse transcriptase (BRL, 
Gaithersburg, MD). Oligonucleotides were designed using Primer3 software 
(available at http://frodo.wi.mit.edu/cgi-bin/primer3/primer3_www.cgi). The 
sequences of the primers were as follows: α-ENaC, 5’-gagagcctggcacagagagg-3’ 
(sense), 5’-cggctttcacgccctcttg-3’ (antisense); β-ENaC , 5’-tttggcttccagcctgacaca-
3’(sense), 5’-cgggatgggcagagtctgtt-3’(antisense); γ-ENaC,5’-ccttcaagctgagcgaac 
ct-3’(sense),5’-gatgtttgtgacgggcacatc-3’(antisense). qPCR amplification was 
performed using the SYBR Green Master Mix (Applied Biosystems) and the 
Prism 7500 Real-Time PCR Detection System (Applied Biosystems). Cycling 
conditions were 95°C for 10 min, followed by 40 repeats of 95°C for 15 s and 
60°C for 1 min. 
 
Data analysis 
Data are summarized as mean + SE. Statistical analysis was performed 
using one-way ANOVA or student paired t-test as appropriate. 
 
 




RGZ and PPARγ knockout do not affect ENaC  
expression in renal inner medulla 
To examine the effect of PPARγ agonists on ENaC expression, we 
performed RGZ and vehicle treatment on wild type (WT) and CD PPARγ KO 
mice (KO) for 9 days. Inner medullas were dissected from mouse whole kidneys. 
mRNA expression of the 3 ENaC subunits (α-, ß-, and γ-) was subsequently 
determined by using qRT-PCR. Figure 3.1 summarizes the mRNA expression of 
the ENaC α, ENaCß, ENaCγ subunits in WT and CD PPARγ KO inner medullas. 
Nine days RGZ treatment had no effect on ENaC α, ENaCß expression. There is 
a reduced trend on ENaCγ expression but it did not reach  statistical significance. 
We also did not observe the ENaC expression difference between KO-Vehicle 
and WT-Vehicle groups. These findings demonstrate that RGZ and PPARγ 
knockout do not affect ENaC expression in renal inner medulla. 
 
RGZ inhibits ENaC activity and expression in primary culture cells  
 ENaC represents the major route of transcellular transport in the CD and 
is reported to be variably regulated by PPARγ. We performed the Ussing 
chamber technique to examine the effect of RGZ on ENaC activity and 
expression in primary cultures of mouse IMCD cells. The confluent IMCD cell 
monolayers were fasted with serum-free media for 4 h, followed by exposure to 1 
µM RGZ for 24 or 48 h. Electromicroscopy confirmed formation of the tight 
junction that was not obviously affected by RGZ treatment (data not shown). The 
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amiloride-sensitive currents were used as an index of ENaC activity. The ENaC 
activity was unaffected at 24 h but was significantly reduced at 48 h of RGZ 
treatment (Fig.3.2). mRNA  expression of the 3 ENaC subunits (α-, ß-, and γ-) 
was subsequently determined by using qRT-PCR. The pattern of changes in 
mRNA expression in response to RGZ treatment was similar among the 3 ENaC 
subunits. At 24 h, the expression level in the RGZ group tended to be lower than 
in the control group but this difference did not reach statistical significance (Fig. 
3.3A). The difference became significant at 48 h (Fig. 3.3B).  
 
RGZ reduces the TER  
The changes in the TER are inversely related epithelial transport rate with 
low TER typically reflecting increased ion transport across the cell monolayer. 
We examined the effect of RGZ on the TER in primary cultures of IMCD cells. 
The exposure of IMCD cell monolayers to 1 µM RGZ decreased the TER by 50% 
(P < 0.01) at 24 h and by 70% at 48 h (P < 0.01) (Fig. 3.4). Since ENaC was 
suppressed, the reduction of the TER seemed to indicate an alternative route of 
increased ion flux.  
 
Discussion 
PPARγ is a ligand-activated transcriptional factor that heterodimerizes 
with RXR to regulate expression of a wide range of target genes involved in 
adipogenesis, glucose uptake, and inflammatory response. Recently, renal action 
of PPARγ has received fresh attention particularly due the relevance to TZD-
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induced fluid retention, the major side effect of the promising antidiabetes drugs. 
Within the kidney, PPARγ is expressed predominantly in the CD, with low or 
absent levels of expression in proximal tubule and thick ascending limb, as 
assessed by both microdissection coupled with RT-PCR and in situ hybridization 
techniques (16,17). Thus, the CD is a likely target site for renal action of PPARγ. 
Conditional deletion of PPARγ in the CD in mice completely abolished or 
significantly attenuated RGZ-and pioglitazone-induced body weight gain and 
plasma volume expansion. These studies have identified a PPARγ-dependent 
pathway in the control of fluid reabsorption in the distal nephron which is 
essential for fine-tuning adjustment of urinary excretion of water and electrolytes. 
These findings are of clinical importance for understanding pharmacology of the 
antidiabetes drugs and may also be of physiological relevance based on the 
existence of a number of endogenously produced products that may act on 
PPARγ in the CD; most of these products are lipid metabolites, including nitrated 
free fatty acids (25,26), 15-deoxy-delta(12,14)-prostaglandin J2 (15d-PGJ2) 
(27,28),  and  lysophosphatidic acid (31).  Therefore, it is critically important to 
understand the mechanism by which PPARγ regulates distal tubular fluid 
reabsorption.  
 The aim of the present study was to perform RGZ treatment on WT and 
KO mice and electrophysiological studies on primary cultures of CD cells to 
evaluate involvement of the ENaC in RGZ-induced stimulation of ion transport. 
Data shows RGZ and PPARγ knockout do not affect ENaC expression in renal 
inner medulla.  There is a big standard deviation in each group in this in vivo 
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experiment, but ENaCγ expression still shows a reduced trend after RGZ 
treatment which is consistent with the results in primary cultures of CD cells. We 
found that RGZ treatment time-dependently inhibited amiloride-sensitive Isc, a 
measure of ENaC activity. The effect was not detectable until 48 h, suggesting a 
slow process.  This finding was further confirmed at mRNA levels. At 48 h, RGZ 
treatment consistently suppressed mRNA expression of all ENaC subunits (α-, ß-
and γ-).  Given ENaC being the major Na+ transporter on the apical membrane of 
the CD, these findings indicate that PPARγ may inhibit transcellular Na+ 
transport. Despite the inhibition of transcellular Na+ transport, the TER was 
consistently reduced following RGZ treatment, indicating an alternative route of 
increased ion transport.  
 ENaC was initially considered as a possible target of PPARγ in the CD 
cells. This possibility was first suggested by the study of Hong et al. showing a 
translocation of α-ENaC accompanied with an upregulation of SGK1 mRNA and 
activity in cultured human CCD cells after a 4-h exposure to PPARγ agonists 
(30).  Subsequently, in IMCD cells, pioglitazone treatment was shown to rapidly 
induce γ-ENaC mRNA expression without affecting expression of α-, and ß-
ENaC subunits (19).  Recently, evidence suggests that PPARγ agonist treatment 
may induce alteration in banding patterns of renal γ-ENaC protein which were 
described as activating cleavage (31,32). However, emerging evidence argues 
against ENaC as a molecular target of PPARγ. First, none of the 3 ENaC 
subunits exhibited major changes in renal mRNA expression in response to a 2- 
or 4-day PPARγ agonist treatment in vivo (24). Second, in various CD cell lines, 
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PPARγ agonists failed to enhance basal or insulin-stimulated Isc (23). Third, and 
more importantly, CD-specific gene inactivation of α-ENaC in the mouse does not 
attenuate RGZ-induced body weight gain or plasma volume expansion, virtually 
ruling out involvement of ENaC (33). Along this line, the present study found no 
evidence of RGZ-induced increases in ENaC activity or expression in primary CD 
cells, similar to the study in CD cell lines (23). Interestingly, we found that RGZ 
treatment time-dependently inhibited ENaC activity and mRNA expression in 
primary CD cells. In the Nofziger et al. study, a similar inhibitory effect of PPARγ 
agonist on Isc was noticed only in M1 but not the A6 or mpkCCDc14 cell lines 
and also with one PPAR agonist GW7845 but not the other (pioglitazone). The 
inconsistent results may be related to the short time course of drug treatment 
(18-24 h) used in the previous study (23). Indeed, we found that the inhibition did 
not occur until 48 h of RGZ treatment. The mechanism by which PPARγ 
suppresses ENaC expression in renal CD cells still remains elusive. A seminal 
study by Pascual et al. demonstrates that PPARγ-dependent transcriptional 
suppression of inflammatory response genes in mouse macrophages involves 
ligand-dependent SUMOylation of the PPARγ ligand-binding domain and 
subsequent recruitment of nuclear receptor corepressor (NCoR)-histone 
deacetylase-3 (HDAC3) complexes on inflammatory gene promoters (34). Future 
studies are needed to determine whether a similar mechanism may underlie 
PPARγ-induced repression of ENaC expression in renal CD cells.  
 
 








Fig. 3.1.  Effect of RGZ on ENaC mRNA expression in renal inner medulla of wild 
type (WT) and CD PPARγ KO mice (KO). The WT and KO mice were treated 
with RGZ and Vehicle for 9 days. mRNA expression of α-, β-, and γ-ENaC was 
determined by qRT-PCR and normalized by β-actin.  Data are mean + SE. N = 4 




















Fig.3.2. Effect of RGZ on amiloride-sensitive Isc in primary IMCD cells.  The 
confluent cell monolayers were fasted with serum-free media for 4 h, followed by 
treatment with vehicle or 1 µM RGZ for 24 h (A) or 48 h (B). At the end of the 
experiments, the Isc was measured in the absence or presence of 100µM 














Fig. 3.3.  Effect of RGZ on ENaC mRNA expression in the IMCD cells.  The 
confluent IMCD cells were exposed to vehicle or 1 µM RGZ for 24 h (A) or 48 h 
(B). mRNA expression of α-, β-, and γ-ENaC was determined by qRT-PCR and 
normalized by β-actin. *, P < 0.05 and **, P < 0.01 vs. Control.  Data are mean + 


















Fig. 3.4. Effect of RGZ on the TER in the IMCD cells. The confluent cell 
monolayers were fasted with serum-free media for 4 h, followed by treatment 
with vehicle or 1 µM RGZ for 24 h (A) or 48 h (B). *, P < 0.05 vs. Control.  The 
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 CHAPTER 4 
 
SUMMARY AND PERSPECTIVES 
 
Edema and fluid retention are common and serious side effects of TZD 
therapy, which are due to supernormal sodium reabsorbtion and consequent 
interstitial fluid volume expansion. We have developed a mouse model with CD-
specific deletion of the PPARγ gene and characterized a novel PPARγ-
dependent pathway in regulation of sodium transport in the distal nephron. Body 
weight gain and plasma volume expansion in response to RGZ treatment were 
abolished or significantly blocked by knocking out PPARγ in the CD. Our study 
proved that PPARγ plays a critical role in systemic fluid retention through the 
regulation of renal sodium transport, and that the adverse effects of TZD in fluid 
metabolism are indeed PPARγ-dependent. These findings are of clinical 
importance for understanding pharmacology of the antidiabetes drugs and may 
also be of physiological relevance based on the existence of a number of 
endogenously produced products that may act on PPARγ in the CD. Therefore, it 
is critically important to understand the mechanism by which PPARγ regulates 
distal tubular fluid reabsorption.  
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We examined the inner medulla mRNA expression of α-, ß-, and γ-ENaC in RGZ 
treated mice, data shows RGZ and PPARγ knockout do not affect ENaC 
expression in renal inner medulla. We performed electrophysiological studies on 
primary cultures of inner medullary collecting duct (IMCD) cells to evaluate 
mechanisms of rosiglitazone (RGZ)-stimulated ion transport.  Following exposure 
to RGZ, amiloride-sensitive short-circuit current (Isc), an index of ENaC activity, 
was unchanged at 24 h but was significantly suppressed at 48 h, corresponding 
to parallel inhibition of mRNA expressions of α-, ß-, and γ-ENaC. Despite ENaC 
inhibition, the transepithelial resistance (TER) was significantly reduced, 
suggesting an alterative route of increased ion transport. In summary, these data 
indicates that ENaC is not critical for rosiglitazone (RGZ)-stimulated ion 
transport.  
Recently, my colleagues in our lab examined the effect of RGZ on 
paracellular Na+ and Cl- flux. RGZ treated monolayers exhibited increases of the 
paracellular Cl- flux, to a lesser extent, the paracellular Na+ flux.  In contrast, 
these effects were significantly blunted in the PPARγ-deficient IMCD cells. In wild 
type IMCD cells, together, our data suggest that PPARγ activation stimulates 
paracellular ion transport and inhibits ENaC in primary IMCD cells. These data 
suggest that the paracellular rather than transcellular route might be a primary 
target of PPARγ in the CD. 
 
 
